Search Results - "Zografos, E"

Genetic variability of the HPV16 early genes and LCR. Present and future perspectives by Bletsa, G, Zagouri, F, Amoutzias, G D, Nikolaidis, M, Zografos, E, Markoulatos, P, Tsakogiannis, D

“…Human papillomavirus 16 (HPV16) infection is the aetiologic factor for the development of cervical dysplasia and is regarded as highly carcinogen, because it…”
Get more information

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial by Guo, Y., Ahn, M.-J., Chan, A., Wang, C.-H., Kang, J.-H., Kim, S.-B., Bello, M., Arora, R.S., Zhang, Q., He, X., Li, P., Dechaphunkul, A., Kumar, V., Kamble, K., Li, W., Kandil, A., Cohen, E.E.W., Geng, Y., Zografos, E., Tang, P.Z.

“…Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after…”
Get full text

Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer by Papanikolaou, I. G., Dimitrakakis, C., Zagouri, F., Marinopoulos, S., Giannos, A., Zografos, E., Zografos, C. G., Kritikou, D., Rodolakis, A., Zografos, G. C., Loutradis, D.

“…Background The emphasis on aesthetic outcomes and quality of life after breast cancer surgery has motivated breast surgeons to develop oncoplastic breast…”
Get full text

Identification of serum proteome signatures of male breast cancer by Zografos, E., Anagnostopoulos, A., Papadopoulou, A., Legaki, E., Zagouri, F., Marinos, E., Tsangaris, G., Gazouli, M.

Get full text

Fulvestrant and male breast cancer: a case series by Zagouri, F., Sergentanis, T.N., Chrysikos, D., Zografos, E., Rudas, M., Steger, G., Zografos, G., Bartsch, R.

Get full text

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer by Mirza, Mansoor R., Chase, Dana M., Slomovitz, Brian M., dePont Christensen, René, Novák, Zoltán, Black, Destin, Gilbert, Lucy, Sharma, Sudarshan, Valabrega, Giorgio, Landrum, Lisa M., Hanker, Lars C., Stuckey, Ashley, Boere, Ingrid, Gold, Michael A., Auranen, Annika, Pothuri, Bhavana, Cibula, David, McCourt, Carolyn, Raspagliesi, Francesco, Shahin, Mark S., Gill, Sarah E., Monk, Bradley J., Buscema, Joseph, Herzog, Thomas J., Copeland, Larry J., Tian, Min, He, Zangdong, Stevens, Shadi, Zografos, Eleftherios, Coleman, Robert L., Powell, Matthew A.

“…A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free…”
Get full text

64PIdentification of serum proteome signatures of male breast cancer by Zografos, E, Anagnostopoulos, A, Papadopoulou, A, Legaki, E, Zagouri, F, Marinos, E, Tsangaris, G, Gazouli, M

Get full text

548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study by Tinker, A.V., Pothuri, B., Gilbert, L., Sabatier, R., Brown, J., Ghamande, S., Mathews, C., O'Malley, D., Boni, V., Gravina, A., Banerjee, S., Miller, R., Pikiel, J., Mirza, M.R., Duan, T., Antony, G., Zildjian, S., Zografos, E., Veneris, J., Oaknin, A.

Get full text

549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study by André, T., Berton-Rigaud, D., Curigliano, G., Sabatier, R., Tinker, A.V., Oaknin, A., De Braud, F.G.M., Ellard, S., Arkenau, H-T., Trigo Perez, J.M., Brown, J., Jewell, A., Pikiel, J., Mirza, M.R., Duan, T., Antony, G., Zildjian, S., Zografos, E., Veneris, J., Banerjee, S.

Get full text

120P Discovery of prognostic biomarkers in Ewing sarcoma by Kyriazoglou, A., Moutafi, M., Zografos, E., Konteles, V., Sofianidis, G., Mahaira, L., Papakosta, A., Tourkantoni, N., Patereli, A., Stefanaki, K., Tzotzola, V., Baka, M., Polychronopoulou, S., Dimitriadis, E., Kattamis, A.

Get full text

57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results by Peters, S., Lim, S.M., Ortega Granados, A.L.O., Pinto, G.D.J., Fuentes, C.S., Lo Russo, G., Schenker, M., Ahn, J.S., Reck, M., Szijgyarto, Z., Huseinovic, N., Zografos, E., O’Donnell, S., de Marinis, F.

Get full text

Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial by Machiels, J-P., de Castro, G., de Souza Viana, L., Galiulin, R., Tahara, M., Nicolau, U.R., Le Tourneau, C., Okami, K., Vladimirov, V., Izmailov, A., Hoermann, K., Licitra, L., Haddad, R., Cohen, E., Dupuis, N., Love, J., Zografos, E., Ehrnrooth, E., Fayette, J.

Get full text

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial by Guo, Y, Ahn, M-J, Chan, A, Wang, C-H, Kang, J-H, Kim, S-B, Bello, M, Arora, R S, Zhang, Q, He, X, Li, P, Dechaphunkul, A, Kumar, V, Kamble, K, Li, W, Kandil, A, Cohen, E E W, Geng, Y, Zografos, E, Tang, P Z

“…Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after…”
Get full text

Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease by Thomas, Diamantis, Gazouli, Maria, Karantanos, Theodoros, Rigoglou, Stella, Karamanolis, Georgios, Bramis, Konstantinos, Zografos, George, Theodoropoulos, George E

“…AIM:To investigate the correlation between rs1568885,rs1813443 and rs4411591 polymorphisms and response to infliximab in a cohort of Greek patients with…”
Get full text

Unintentional Childhood Poisoning in Athens: A Mirror of Consumerism? by Petridou, Eleni, Polychrionopoulou, Argy, Kouri, Nikoletta, Karpathios, Themistoklis, Koussouri, Mary, Messaritakis, Yannis, Mathioudakis, Yannis, Siafas, Konstantinos, Tsitsika, Helen, Zografos, Evangelos

“…Objective : To estimate the incidence of unintentional childhood injuries resulting from accidental poisonings in the Greater Athens area and to ascertain what…”
Get full text

Further characterization of macrophage adsorption of suppressor cell activity from tumor-allosensitized spleen by Zografos-Miller, L E, Argyris, B F

“…Suppressor cell activity from P815-allosensitized C57BL/6 spleen can be decreased by incubating the tumor-allosensitized spleen cells on monolayers of…”
Get more information